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Type I interferon (IFN-I) play a critical role in the innate immune response against viral infections.They actively participate in anti-
viral immunity by inducing molecular mechanisms of viral restriction and by limiting the spread of the infection, but they also
orchestrate the initial phases of the adaptive immune response and influence the quality of T cell immunity. During infection
with the human immunodeficiency virus type 1 (HIV-1), the production of and response to IFN-I may be severely altered by the
lymphotropic nature of the virus. In this review I consider the different aspects of virus sensing, IFN-I production, signalling, and
effects on target cells, with a particular focus on the alterations observed following HIV-1 infection.
1. Introduction
Interferons (IFN) are a heterogeneous class of soluble imm-
une mediators which were originally defined by their ability
to interfere with the replication of diverse types of viruses in
vitro and in vivo. Human type I IFN (IFN-I) include IFN-𝛼
(14 genes, resulting in more than 22 products) and IFN-𝛽,
both encoded by genes clustered on chromosome 9, probably
generated as a result of gene duplication events, as epitomized
by the presence of multiple pseudogenes [1]. IFN-𝜀, IFN-𝜅,
IFN-𝜏, and IFN-𝜔 have also been described in mammals as
members of the IFN-I family. This review is focused on the
literature covering the regulation and the function of IFN-𝛼
and IFN-𝛽.
IFN-I are produced in large quantities in response to viral
infections and are generally regarded as a key bridgingmech-
anismbetween innate and adaptive immune responses, exert-
ing both antiviral activity, and immunostimulatory functions,
such as promoting antigen-presenting cell maturation and
molding T helper cell responses [2–8]. However, the notion
that IFN-I serve only as effector immune mechanisms may
need to be revised based on accumulating evidence which
highlights the potent immunoregulatory ability of these mol-
ecules. During chronic viral infections, the beneficial antivi-
ral and immunostimulatory effects of IFN-Imay be overruled
by the prolonged stimulation of IFN-I-induced cytostatic and
proapoptotic mechanisms.
Infection by the human immunodeficiency virus type 1
(HIV-1) may represent an extreme example of how chronic
IFN-I production progressively undermines the development
of efficient long-term antiviral immunity [9, 10].
Different cells have the potential to produce IFN-I and
the mechanism by which viral insults are sensed varies depe-
nding on the cell type, as does the potency of the IFN-I-pro-
ducing response. In the case of HIV-1, most studies have
focussed on plasmacytoid dendritic cells (pDC) as the main
producers of IFN-I following viral exposure [9, 11, 12]. How-
ever, recent evidence indicates that the source and dynamics
of IFN-I production may change during the course of infe-
ction, and pDC may be replaced by myeloid dendritic cells
(mDC) and monocytes/macrophages as the main source of
IFN-I during the transition from acute to chronic infection
[13].
Based on themolecularmechanisms of viral sensing invo-
lved in HIV-1 recognition by different cells (1), the evidence
available on IFN-I production by different cell types during
the acute and chronic phases of infection (2) and the combi-
nation of antiviral and immunomodulatory activity of IFN-I
(3), it is possible to speculate that IFN-I may serve different
purposes during different stages of chronic infections, and
that the dysregulation of IFN-I production during HIV-
1 infection may contribute to progressive immunodefici-
ency.
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2. Viral Sensing by
Pattern Recognition Receptors
Innate sensing of virus-related pathogen associated molecu-
lar patterns (PAMP) relies primarily on recognition of viral
nucleic acids by toll-like receptors (TLR) in the endosomes
of specialised immune cells, or by cytoplasmic sensors widely
expressed by different cell types and not restricted to immune
cells [14–19].
HIV-1 interacts with and infects cells expressing CD4,
which is engaged by the viral envelope glycoprotein gp120.
Thus, IFN-I production duringHIV-1 infection ismainly sus-
tained by immune cells which are either exposed to or infe-
cted by HIV-1.
2.1. Toll Like Receptors. Toll-like receptors are a family of
pattern recognition receptors (PRR) preferentially expressed
by cells which participate in the innate immune responses
against invading pathogens [14–16]. At least four TLR have
the potential to sense viral nucleic acids in humans. Signalling
via TLR3, TLR7, and TLR8 is triggered by viral RNA, whereas
TLR9 recognizes unmethylated CpG-rich DNA sequences
[15, 20]. Although RNA-sensing TLR have the potential to
recognizeHIV-1, only TLR7-expressing pDCappear to respo-
nd promptly to viral exposure. Conversely, the available evi-
dence either excludes or is inconclusive regarding the ability
of HIV-1 to directly activate cells expressing TLR8 or TLR3,
such as mDC and MΦ, but also microglia and astrocytes
within the central nervous system [12, 21–23].
The ability of pDC to respond to HIV-1 stimulation appe-
ars to bemainly dependent on TLR7 signalling [24], although
a role for TLR9 cannot be excluded [12].TheHIV-1 viral cycle
includes the formation of a DNA/RNA heterodimer and a
double stranded DNA proviral DNA, which represent pote-
ntial ligands for TLR9 via CpG-rich DNA regions. Partial
reverse transcription may occur already in the virion, due
to the packaging of complexes formed by reverse transcrip-
tase, viral RNA genome and transfer RNA primer [25–27].
However, the reverse transcription process is completed in
the cytoplasmic environment [25, 27], secluded from endo-
somal TLR9. Whether fragment of DNA of viral origin
included in the virion engulfed by pDC and processed via the
endosomal pathway can trigger TLR9-mediated responses
remains untested.
Engagement of TLR7/9 results in the activation of a
complex network of transduction signalling pathways in
pDC. The first step required for TLR7/9 signal transduction
is the recruitment of the adaptor molecule myeloid differen-
tiation primary-response gene 88 (MyD88), which in turn
associates with other adaptor and signalling molecules to
form a complex comprised of TNF-receptor-associated factor
(TRAF)6, Bruton’s tyrosine kinase (BTK), IL-1R-associated
kinase (IRAK)4 and IRAK1 [20, 28, 29]. The signalling com-
plex catalyzes the activation of different intracellular path-
ways.
The pathwaymediated by the interferon regulatory factor
(IRF)7 is directly associated with activation of IFN-𝛼 and
IFN-𝛽 genes following nuclear translocation of IRF7 [30].
Signalling through the IRF7 pathway is dependent on the
activation of phosphatidylinositol 3-kinase (PI3K)-𝛿 [31].
IFN-𝛼/𝛽 secreted during this early phase may act in an
autocrine manner through the dimeric type I IFN receptor
(IFNAR) and stimulate de novo production of IRF7, further
stimulating IFN-I secretion in a potent positive feedback
loop of IFN-I production [28]. The IRF7-mediated signall-
ing pathway is therefore responsible for the differentiation of
pDC into efficient IFN-I producing cells (IPC). PI3K and
IRF7 signalling is not required for the production of tumor
necrosis factor (TNF)-𝛼, interleukin (IL)-6, and the che-
mokines CXCL10 and CCL3, which rely on the canonical
nuclear factor (NF)-𝜅B pathway (Rel-A: p50 dimer) which
in turn requires mitogen-activated protein kinase p38 (p38-
MAPK) activity [32]. The same pathway is responsible for
promoting the expression of the costimulatory molecules
CD80 and CD86, which are conditions necessary for the
maturation of pDC into fully competent antigen presenting
cells (APC) [32]. TLR7/9 engagement also promotes upregu-
lation of the immunoregulatory enzyme indoleamine (2,3)-
dioxygenase (IDO) in both murine and human pDC [33–
36]. In murine models, IDO regulation via TLR7/9 occurs
following activation of the noncanonical NF-𝜅B pathway
(Rel-B: p52 complex) [37], and non-canonical NF-𝜅B is also
required to support IFN-𝛼 production [38].
IRF7 and NF-𝜅B are not simultaneously activated follow-
ing TLR7/9 engagement, and the pathway which dominates
the signalling cascade is determined by the intracellular
compartment where TLR7/9 engagement occurs [39].
2.2. Cytoplasmic RNA Sensors. TLR represent powerful mec-
hanisms for viral recognition, but their expression is limited
to immune cells and the restriction to endosomal comp-
artment prevents them from detecting viruses which have
reached the cytoplasmic environment. Retinoic acid-indu-
cible gene 1 (RIG-I)-like receptors (RLR) are a family of PRR
broadly expressed among different human cells, and confer
the ability to sense virus-derived RNA within the cytopl-
asm [15, 17, 18]. RLR include RIG-I, melanoma differentia-
tion factor (MDA)5, and laboratory of genetics and phys-
iology (LGP)2 protein, all of which are potently upregulated
by IFN-I [40]. Studies conducted in transgenic mice sug-
gest that different RLR are critical in the recognition of
and IFN-I response against different viruses [18]. How-
ever, it remains unclear how RLR distinguish viral RNA
from cellular RNA, and therefore trigger IFN-I produc-
tion only in infected cells. The specificity for exogenous
RNA may be dependent on the recognition of second-
ary structures which are common in viral RNA genomes
[18]. RLR signal transduction occurs through binding of
the receptor to the mitochondrial adaptor IFN-𝛽 prom-
oter stimulator (IPS)-1 and formation of a signalling com-
plex leading to the activation of the kinases TNF rece-
ptor-associated factor (TRAF)-associated NF-𝜅B actvator
(TANK) binding kinase (TBK)1-IK𝛽 kinase (IKK)𝜀 [40]. The
TBK1-IKK𝜀 is then responsible for both IFN-I production via
IRF3 and IRF7 and for NF-kB activation [40].
Berg and colleagues demonstrated that genomic HIV
RNA can trigger inflammatory responses in human periph-
eral blood mononuclear cells (PBMC) via RIG-I recognition,
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leading to production of the interleukin (IL)-6, TNF-𝛼,
IFN-𝛼, and IFN-𝛽 [41].The cellular sources of the proinflam-
matory cytokines were not investigated in this study. It
is plausible that, during HIV-1 infection in vivo, all cells
susceptible of infection have the potential to respond to
HIV-1 genomic RNA via RIG-I sensing. However, the nature
of the responses may differ depending on the target cells,
and inflammatory responses may be differentially mediated
by DC and monocyte/macrophages compared to CD4 T
lymphocytes.
2.3. Cytoplasmic DNA Sensors. The presence of a RNA-
DNA hybrid during reverse transcription of the HIV-1 RNA
genome into dsDNA suggests that cytoplasmic recognition of
the proviral DNA may occur before its translocation to the
nucleus and integration into the host genome.
The cytosol of eukaryotic cells is rich in enzymes with
DNase activity, which prevent accumulation of DNA in the
cytoplasm [42]. However, when the preventive measures
exerted by cytoplasmic DNases fail, DNA of viral origin
may accumulate in the cytoplasm. Double stranded DNA
is a potent immune stimulator when present in the cytosol
of target cells [43, 44], and recent evidence indicates that
single-stranded DNA with specific signatures, such as AT-
rich regions, is also a strong activator of immune responses
[45]. Sensing of cytoplasmic DNA triggers a cascade of signal
transduction orchestrated by the adaptormolecule stimulator
of interferon genes (STING) [46–49], leading to the produc-
tion of proinflammatory and antiviral cytokines, including
IFN-I [48]. STING engages TBK1 to cause IRF3 activation,
and the STING-TBK1-IRF3 signaling axis is critical for IFN-I
induction by cytosolic DNA [50].
Recent evidence indicates that cytosolic HIV-1-derived
dsDNA or RNA/DNA heterodimersmay trigger innate imm-
une responses. Gao and colleagues have used both themono-
cytic cell line THP1 and primary human monocyte-derived
macrophages and dendritic cells to show that HIV infection
induces the production of cyclic guanosine monophosphate-
adenosine monophosphate (cGAMP), which binds to and
activates STING resulting in the production of IFN-I [51].
The production of IFN-𝛽 was strictly dependent on reverse
transcription, indicating that HIV-1 DNA acts as the initial
trigger for IFN-I production [51]. Furthermore, Jakobsen and
colleagues have shown that ssDNA generated from HIV-1
proviral genome is a potent activator of IFN-I in primary
humanmonocyte-derivedmacrophages [52]. Single stranded
HIV-1 DNA engages the IFN-inducible protein 16 (IFI16) in
the cytoplasmofmacrophages, leading to the activation of the
STING-TBK1-IRF3 pathway [52].
3. Cellular Sources of IFN-I during
HIV-1 Infection
3.1. Plasmacytoid Dendritic Cells. Plasmacytoid DC are the
most potent producers of IFN-I in response to viral infections
[16, 53, 54]. Expression of endosomal TLR7 and TLR9 allows
pDC to respond to both RNA and DNA viruses which
are engulfed and trafficked into the endosomal pathway.
Upon TLR7/9 engagement, pDC can mature into antigen-
presenting cells (APC) or IFN-I-producing cells (IPC), and
the prevalence of one pathway over the other largely depends
on the intracellular locale in which the TLR ligand triggers its
receptor [23, 39].Thus, the engagement of TLR7/9 within the
early endosomes causes strong activation of the IRF7 pathway
via an IFN-𝛼/𝛽-dependent positive feedback, resulting in the
production of high quantities of IFN-𝛼 and pDC differen-
tiation into IFN-I-producing cells (IPC) [39]. Conversely, if
the TLR ligand is trafficked to the lysosomes or late endo-
somes, signal transduction via the NF-𝜅B pathway is favored,
resulting in the upregulation of costimulatory molecules and
maturation into APC [39]. O’Brien and colleagues reported
that HIV-1 is preferentially trafficked to the early endosomes
of pDC, which in turn promotes a persistently activated IPC
status, combined with partial or incomplete maturation [23].
The binding of the HIV-1 envelope glycoprotein gp120 to
CD4, but not to the coreceptors CCR5 or CXCR4 is required
for virion engulfment and subsequent activation of pDC via
TLR7 engagement [12, 55]. The interaction between gp120
and CD4 is stabilized by accessory interactions involving
cellular adhesion molecules on both the cell membrane and
viral envelope, allowing the formation of a stable binding
interface between HIV-1 and the target cells [56–58]. Thus,
the envelope of newly formed HIV-1 virions incorporates
cellular proteins derived from the host cell of origin [56,
57, 59]; these cell-derived proteins contribute to virus-cell
interactions and may modulate the dynamics of infection
of target cells and uptake by endocytotic cells [57–60]. In
addition, the HIV-1 envelope is not homogenous, but rather
organized in a functional substructure enriched in tightly
packed cholesterol, similar to the lipid rafts described in
eukaryotic cells, including human leukocytes [9, 60, 61]. The
organization of a functional virion-associated lipid raft is
required to confer HIV-1 the ability to induce potent IFN-I
production via pDC stimulation [9]. Thus, the efficiency of
HIV-1 uptake by pDC and the potency of IFN-I induction
are strongly reduced if envelope-associated cholesterol is
withdrawn by chemical treatment [9]. However, cholesterol
depleted HIV-1 partially retains the ability to promote pDC
maturation into APC [9], suggesting that the integrity of the
virion-associated lipid raftmay not only reduce the efficiency
of HIV-1 uptake, but also modify the dynamics of HIV-1
trafficking and subsequent TLR signalling in favour NF-𝜅B-
mediated APCmaturation rather than IRF7-dependent IFN-
𝛼 production.
Activation of pDCmayoccurwithin hours fromexposure
to HIV-1 in vivo. Intravaginal infection of rhesus macaques
caused rapid accumulation of activated pDC at the mucosal
site of infection, which resulted inmacrophage inflammatory
protein (MIP)-3𝛼-mediated chemoattraction and infection
of CCR5-expressing CD4 T cells, contributing to the spread
of the infection to secondary lymphoid tissues [62]. Lubong
Sabado and colleagues reported that pDC relocate to lym-
phoid tissues already during primary HIV-1 infection, a con-
dition which persists throughout the course of disease [63].
However, reports on IFN-𝛼 secretion by pDC in lymphoid
tissues during chronic HIV-1 infection showed contrasting
results. For example, although IFN-𝛼 and upregulation of
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IFN-stimulated genes (ISG) has been reported in tissues from
HIV+ patients [64, 65], Nascimbeni and colleagues showed
that pDC in the spleen of HIV-infected patients have an
immature phenotype and do not contribute to the increased
IFN-𝛼 production [66]. The state of partial or incomplete
pDCmaturation is confirmed in the study by Benlahrech and
colleagues, who have recently shown that expression of the
immunoglobulin-like transcript (ILT) 7, a regulatory receptor
expressed by immature circulating pDC but not partially
differentiated cells [36], is reduced in pDC fromHIV-infected
patients when viral replication is not efficiently controlled by
therapy [67].
Recent evidence suggests that pDC may be the predo-
minant source of IFN-I only during the initial phases of
acute infection, whereas mDC and macrophages become
important producers of IFN-𝛼 when the course of infection
transitions to the early chronic phase [13]. Both mDC and
monocyte/macrophages express TLR8, which has the poten-
tial to recognize viral RNA [68, 69]. However, several studies
have shown that in vitromaturation ofmDCandmonocyte in
presence of HIV-1 is a bystander effect occurring in response
to cytokines produced by HIV-1-activated pDC, such as IFN-
𝛼 and TNF-𝛼 [12, 21–23]. In addition, even in conditions
in which TLR8 engagement occurs, mDC do not respond
by secreting IFN-I, but rather mature into interleukin (IL)-
12-secreting APC [68, 69]. Thus, IFN-I production by mDC
and macrophages during the post-acute and chronic phases
of HIV-1 infection may depend on molecular pathways
other than sensing of extracellular viral particles virus via
endosomal TLR.
3.2. Monocytes/Macrophages and Myeloid Dendritic Cells.
Endosomal TLR allow recognition of nucleic acids from
viruses engulfed by specialized cells, but may not sense
viral genomes which have gained access to the cytoplasm.
Intracellular RLR and DNA sensors are triggered by viral
genome in the cytoplasm and induce the production of
antiviral and immunostimulatory cytokines, such as IFN-𝛼
and TNF-𝛼 [18]. RLR are expressed by most cell types and
their triggering requires that the viral genome has reached
the cytoplasm, a condition which is also necessary to achieve
productive infection of the target cell. Conversely, TLR7/9-
mediated pDC responses would not be triggered during a
productive infectious cycle, due to the segregation of the
receptors in the endosomal compartment.Thismay represent
a critical difference between IFN-I responses orchestrated by
uninfected pDC during the early phases of viral exposure and
IFN-I production by productively infected cells during later
stages of infection.
This transition from a pDC-mediated to an apparen-
tly pDC-independent IFN-I response has been recently des-
cribed in the HIV-1 simian model of simian immunodefi-
ciency infection (SIV) of Rhesus macaques by Kader and
colleagues [13]. Monocyte derived macrophages have been
shown to respond to HIV-1 proviral DNA via intracellular
DNA sensors [51, 52], and genomic HIV-1 RNA activates
innate immune responses in peripheralmononuclear cells via
RLR [41]. The question can be raised as to whether the main
source of IFN-I changes during HIV-1 infection in relation
to a shift in the distribution of productively infected cells
among different cell types. Dendritic cells may act as catalysts
for the infection of CD4 T cells via cell-cell transfer [70, 71],
but activated CCR5+ CD4 T cells are the main target for
infection and the main source of viral replication throughout
the acute phase [72, 73]. However, the number of CCR5+ T
cells decreases progressively during acute infection both in
the periphery and in lymphoid tissues, likely due to a com-
bination of viral cytotoxicity, activation-induced apoptosis
and immune-dependent killing mediated by newly activated
HIV-1-specific cytotoxic CD8 T lymphocytes (CTL) [72–74].
Thus, as the pool of CCR5+ CD4 T cells decreases, CD4-
expressing mDC and monocyte/macrophages may become
increasinglymore important as targets for infection, and ther-
efore more susceptible to activation via cytoplasmic RLR.
The critical questions that remain unanswered is whether
the prolonged IFN-I response observed during pathogenic
HIV-1/SIV infection plays a determinant role in viral immu-
nopathogenesis and whether pDC-mediated acute responses
or chronic IFN-I responses mediated by non-pDC subsets
are potentially valuable targets for immunotherapeutic or
curative interventions.
3.3. Other Cellular Sources of IFN-I. The broad expression of
RLR and cytosolicDNA sensors in numerous cell types and in
different tissues [18] suggests that any cell susceptible to HIV-
1 infection, and therefore to cytoplasmic exposure of viral
RNA, has the potential to secrete IFN-𝛼 during HIV-1 infec-
tion. Nonetheless, evidence about IFN-𝛼 production by cells
other than DC and monocytes is scattered and largely incon-
clusive about its relevance for systemic immune activation
and immunopathogenesis. However, IFN-𝛼-producing cell
subsets which are confided to specific anatomic locationsmay
contribute to inflammatory processes within non lymphoid
tissues and organs, partially accounting for the develop-
ment of HIV-1-associated non-communicable comorbidities
(NCCM).An increasing body of evidence suggests a causative
link between chronic inflammation and some manifestations
of NCCM. One example is that of neurological complica-
tions associatedwith neuroinflammation,which are observed
even in patients in whom viral replication in controlled by
combination antiretroviral therapy (cART) [75–77]. Thus,
microglial activation and an IFN-driven gene regulation sig-
nature are characteristic ofHIV-associated neurological sym-
ptoms, such as cognitive impairment and depressive disorder
[75, 76, 78, 79]. It is noteworthy that neurologic disease
associated with infection with another human lymphotropic
retrovirus, the human T-lymphotropic virus type 1 (HTLV-
1), is also associated with an IFN-dominated inflamma-
tory profile. Thus, Tattermusch and colleagues described
an IFN-inducible signature in HTLV-1-associated myelopa-
thy/tropical spastic paraparesis (HAM/TSP) [80, 81]. It is still
unclear whether peripheral sources of IFN-I, such as DC or
macrophages are the sole responsible for the neuropathologic
effects or whether astrocytes and microglial cells are directly
involved in the production of IFN-I during the inflammatory
response. Whether IFN-I production by these cells plays a
role also in the immunopathogenesis of HIV-1 infection is yet
to be determined.
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4. Effect of IFN-I on Target Cells
Type I IFN are the most potent natural mediators of antiviral
activity in humans. The combination of proapoptotic and
cytostatic activity, as well as the direct induction of intracel-
lular viral restriction factors contribute to generate a cellular
environment which is unsuitable for viral replication [1, 3, 82,
83]. The replication of HIV-1 is efficiently inhibited by IFN-
I in vitro, but the potential of IFN-I as antiretroviral agents
during chronic HIV-1 infection in vivo is dubious [84–89].
IFN-I also contribute to the maturation of APC and exert
a modulatory effect on different T cell subsets, therefore
posing the foundations for promoting antigen-specific adap-
tive immune responses and shaping them according to the
invading pathogen [1, 6, 7, 53, 82, 90].
4.1. IFN-𝛼 Receptor Complex and Signalling. The cellular
effects of IFN-I aremediated by the engagement of a common
receptor complex, the IFN-𝛼 receptor complex (IFNAR),
which is expressed at different levels on the surface of virtually
all human cells. The IFNAR complex is a heterodimer of the
two subunits IFNAR1 and IFNAR2. Human IFNAR1 com-
prises an extracellular domain, a transmembrane region and
an intracellular domain of 100 amino acid residues. Three
different forms of IFNAR2 have been described: the full
length receptor chain which includes a 250 residues cytoplas-
mic portion, an alternative form with a shorted intracellular
portion (67 residues) [91, 92] and a soluble form lacking
the transmembrane and cytoplasmic portions [91]. Human
IFNAR2 binds all human IFN-I with higher affinity than
IFNAR1, but the affinity of the IFNAR heterodimer for most
human IFN-I is 10 fold higher than IFNAR2 alone [91, 93, 94].
The cytoplasmic domains of IFNAR1 and IFNAR2 are
associated with the tyrosine kinase (TYK)-2 and janus kin-
ase (JAK)-1, respectively [91]. Upon IFN-I binding to the
IFNAR complex, the tyrosine kinases are activated and orc-
hestrate the signal transduction machinery [95]. TYK-2
and JAK-1 phosphorylate tyrosine residues on the IFNAR,
and phosphorylated tyrosines act as docking sites for the
src-homology-2 (SH2) domains of signal transducer and
activator of transcription (STAT) proteins, which are then
targeted for phosphorylation [96, 97]. STAT1, STAT2, STAT3,
and STAT5 are expressed and activated by IFN-I in most
cell types, whereas IFN-I-induced activation of STAT4 and
STAT6 is limited to lymphocytes [96, 97].
STAT2 is recruited to the IFNAR1 cytoplasmic domain
and is phosphorylated by TYK-2, serving as a lure for STAT1
[98], which is also phosphorylated at tyrosine 701.The STAT1-
STAT2 heterodimer associates with the DNA binding protein
interferon regulatory factor 9 (IRF9) to form a signalling
complex called IFN-stimulated gene factor-3 (ISGF3). The
ISGF3 complex translocates to the nucleus where it promotes
the transcription of IFN-I-stimulated genes (ISG) by inter-
acting with the IFN-stimulated response elements (ISRE),
usually situated within 200 base pairs of the transcription
start site. An additional phosphorilation of STAT1 at serine
727, mediated by protein kinase C-𝛿 (PKC-𝛿), is essential for
efficient transcriptional activity [1, 98]. In addition, STAT1
homodimers can bind to IFN-𝛾-activated site (GAS) in the
promoter region of IFN-I-stimulated genes [99, 100]. Thus,
while IFN-I can activate genes containing either ISRE or GAS
promoter elements, IFN-𝛾 is unable to induce the formation
of ISGF3 and activate genes via ISRE [101]. Signalling via
STAT1-STAT2 is responsible for some of the most commonly
observed effects of IFN-I during chronic HIV-1 infection,
including the activation of proapoptotic and cytostatic genes,
viral restriction factors and immunomodulatory effects [102–
104].
Type I IFN also triggers phosphorylation of STAT3
[105], promoting its dimerization and migration to the nucl-
eus. STAT3 homodimers activate the transcription of genes
containing the enhancer sequence STAT3-binding element
(SBE). Despite sharing high sequence similarity with STAT1,
STAT3 activation induces a gene expression profile distinct
from that dependent on STAT1-STAT2 [106], including genes
of the B cell lymphoma (BCL) family and the oncogene
MYC, which promote proliferation and antagonize apoptosis
[107, 108]. Furthermore, STAT3 is responsible for the sup-
pression of inflammatory responses via IL-10, which directly
counteracts STAT1 activity [109].
IFN-𝛽 also activates the signal transduction pathway
mediated by JAK1 and phosphoinositide 3-kinase (PI3K),
leading to the expression of genes regulated by cyclic adeno-
sine monophosphate (cAMP) via the nuclear translocation of
cAMP-responsive-element (CRE) binding protein (CREB).
Similar to the STAT3-mediated pathway, PI3K signalling can
also result in IL-10 production by DC [110]. However, the
two pahways appear to be independent from each other. The
mammalian target of rapamycin (mTOR) is activated down-
stream of the PI3K signalling cascade [111]. Activation of
mTOR is independent of STAT signalling and does not
modify the gene expression profile, but modulates mRNA
translation by regulating the activation of p70 S6 kinase and
the phosphorylation of the ribosomal protein S6 [112, 113].
The signalling pathway mediated by p38 mitogen-activ-
ated protein kinases (p38-MAPK) and extracellular signal-
regulated kinase (ERK) 1 or ERK2 is also activated by IFN-I.
Thus, genes which contain ISRE and GAS elements in their
promoter region can be upregulated via a STAT-independent
pathwaymediated by p38-MAPK [114–116], and the cytostatic
and antiviral effects of IFN-I are dependent on intact p38-
MAPK signalling machinery [117–120].
It is reasonable to expect that different IFN-I signal
transduction pathways are activated during HIV-1 infection.
However, the STAT1-STAT2 pathway is arguably the best
described in the setting of IFN-I production during HIV-
1 infection. The activation of STAT proteins by HIV-1 was
described in different experimental conditions involving
HIV-1-induced IFN-I production, productive HIV-1 infec-
tion of target cells or simple exposure to viral proteins. Thus,
in vitro exposure of cell lines or primary leukocytes to
whole HIV-1 virions was repeatedly shown to activate STAT-
dependent pathways inCD4T cells and cells of themonocytic
lineage [55, 121, 122]. Interestingly, Renga and colleagues
reported that exposure of monocytic cell lines to the HIV-1
matrix protein p17 was sufficient to activate the JAK1/STAT1
axis and cause upregulation of STAT1 sensitive genes [123],
suggesting that STAT1 activation during HIV-1 infectionmay
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also occur independent of IFN-I production. Simian immun-
odeficiency virus (SIV) infection of nonhuman primates in
vivo resulted in upregulation of gene expression for STAT1,
STAT2 and IRF9 during the acute phase of infection, which
was protracted through the early chronic phase only in
disease susceptible primate species, not in disease resistant
African species [124, 125]. Although signalling via the ISGF3
complex is regulated by post-transcriptional modification of
STAT proteins, not by modulation of STAT and IRF9 gene
expression, the observed increases in the expression of these
molecules in SIV-infectedmacaques [124, 125] is indicative of
enhanced activity of the IFN-I/ISGF3 axis.
The central role played by PI3K in multiple signal trans-
duction pathways renders it difficult to distinguish its partici-
pation in mediating the effects of IFN-I from other biochem-
ical, cellular and molecular events occurring during HIV-1
infection. The contribution of PI3K in neuroinflammation
associatedwithHIV-1 infection has been described [126–128],
but the role of Pi3K/mTOR in HIV-1 immunopathogenesis
remains unclear.
Activation of the p38-MAPK pathway during HIV-1 infe-
ction has been described by several groups [129–139]. How-
ever, studies on the p38-MAPK/ERK pathway have generally
focused on the direct effect of HIV-1 gp120 singalling via
engagement of CD4 or the coreceptors CCR5 and CXCR4
[129, 136–139], rather than IFN-I production. In particular,
activation of p38-MAPK/ERK has been studied in reference
to its role in modulating cell activation and HIV-1 replication
[129–135].
4.2. Expression Pattern of IFNAR. Type I IFN are generally
considered to exert their biologic effect on virtually all human
cells. This broad and noncell specific activity reflects the
prominent innate antiviral function of IFN-I, which needs to
reach any potential target of viral infection.
However, cell-specific differences in the responsiveness
to IFN-I signalling have been observed in humans, partic-
ularly among immune effector cells. Thus, IFN-I inducing
TLR9 agonists, as well as HIV-1, efficiently upregulated the
expression of the IFN-I regulated gene PDL1 on primary
human monocytes and a subset of T lymphocytes, identified
by selective expression of the chemokine receptor CCR5 [21].
Analysis of IFNAR2 expression in T lymphocytes revealed
that this subunit of IFNAR was almost exclusively restricted
to CCR5+ T cell subsets, independent of whether CD4 or
CD8 T cells were considered [21]. A similar restriction of
IFN-I signalling to CCR5+ T cells was observed when HIV-
1-induced upregulation of the T cell activationmarkers CD38
and CD69 was analyzed in vitro [9, 140].
In both humans and non-human primates, CCR5 expres-
sion is generally higher in memory and effector T cell subsets
[141–144], and natural disease-resistant SIV host species,
such as sooty mangabeys, show reduced levels of CCR5+
CD4 T cells compared to disease susceptible hosts such as
humans and Rhesus macaques [142, 143]. The role played
by CCR5 as coreceptor for HIV-1 and SIV Env proteins,
providing the critical mechanism for envelope-membrane
fusion and injection of the viral RNA into the cytoplasm,
provided the basis for investigating how differences in CCR5
expression between different species translate into different
transmission and disease progression phenotype [142, 145].
However, little attention has been given to the possibility that
different profiles of CCR5 expression among primate species
may account for different sensitivity to IFN-I production, and
therefore different patterns of regulation of IFN-I-stimulated
genes during chronic HIV-1 or SIV infection, ultimately
accounting for differences in disease susceptibility.
4.3. Cytostatic and Proapoptotic Effects. Type I IFN are widely
recognized as the most potent natural mediators of antiviral
activity in humans [1, 3]. Because the life cycle of viruses is
directly influenced by the intracellular environment, efficient
antiviral mechanisms have developed to interfere with basic
cellular functions or, in an even more resolute manner,
eliminate infected cells which represent the factories of
viral replication. These goals are achieved by IFN-I via the
upregulation of genes exerting cytostatic and proapoptotic
activities. The broadly effective antiviral mechanisms include
the induction of molecular mechanisms interfering with pro-
tein synthesis and cellular activity, as well as the stimulation
of ligand/receptor-dependent apoptotic pathways and stress
responses. While exerting potent antiretroviral activity, these
mechanisms clearly interferewith basic cellular functions and
carry a potentially destructive risk for the host, hence the
need for tight regulation of both the kinetic of activation and
the restriction to specific anatomical locations.
During HIV-1 infection, the chronic induction of IFN-I
responses may contribute to progressive immunodeficiency
[10, 146].
4.3.1. Ligand-Receptor Mediated Apoptosis. Type I IFN posi-
tively regulates the expression of tumor necrosis factor (TNF)
family members, capable of inducing apoptosis in cells which
express specific receptors. Thus, expression of FAS ligand
(FasL), TNF-related apoptosis inducing ligand (TRAIL) and
programmed death ligand (PDL) 1, are all directly regulated
by IFN-I signalling [21, 146–148].
The contribution of the Fas/FasL system to CD4 T cell
apoptosis during HIV-1 infection is well documented [149–
151], and similar findings were reported for IFN-I-induced
TRAIL and its death receptor (DR)5 [55, 65, 121, 152, 153].
TRAIL expression following HIV-1 exposure or infection has
been described in T cells, monocytes, and pDC [24, 55, 153,
154], and TRAIL expressing pDChave been shown to directly
induce apoptosis of CD4 T cells in HIV-1 infected patients
with high viraemia [153]. TRAIL mediated apoptosis in the
setting of HIV-1 stimulation in vitro was originally reported
to affect CD4 T cells, but not CD8 T cells [55, 65, 152].
Interestingly, TRAIL mediated CD4 T cell apoptosis did not
require productive infection, and TRAIL expressing pDC
were reported to be unable to lyse HIV-1 infected CD4 T
cells [155] possibly favouring the depletion of uninfected
CD4 T helper cells in the face of CD4 T cell viral reservoirs
preservation. However, Zhu et al. later described TRAIL
dependent apoptosis in HIV-1 infected macrophages, as a
result of the downregulation of a decoy receptor [156].
Thus, TRIAL induced apoptosis may contribute to regulating
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the balance between clearance of HIV-1 infected cells and
depletion of CD4 T helper cells.
Upregulation of PDL1 on circulating monocytes and T
cells during HIV-1 infection was originally described to cor-
relate with active viral replication [157]. The report of a
causative link between IFN-I secretion and PDL1 expression
after exposure to HIV-1 also indicated that CCR5 expression
on T cells is associated with sensitivity to IFN-I signalling,
determined by increased expression of IFNAR2 [21]. PDL1
engages its receptor PD1 on T lymphocytes to suppress prolif-
eration and induce apoptosis [158]. During HIV-1 infection,
PD1 is highly expressed by exhausted dysfunctional HIV-1-
specific T cells [159], and blockade of PD1-PDL1 interaction
enhances HIV-1-specific T cell immunity and immune-med-
iated control of viraemia in humanized mice and simian
models of HIV-1 infection [160–164]. Thus, upregulation of
PDL1 via IFN-I may directly contribute to the impairment of
efficient antiviral T cell responses and to the perpetuation of
HIV-1 infection.
4.3.2. P53-Mediated Apoptosis. The existence of a functional
connection between IFN-𝛼/𝛽 and p53 we formally reported
by Takaoka and coworkers in 2003 [165]. The relevance
for IFN-I-induced p53 activation for viral infections was
highlighted by Vilcˇek, who postulated that IFN-I-mediated
activation of the STAT1-STAT2-IRF-9 complex (ISGF-3)
during viral infection may promote p53 gene expression via
two ISRE sites in the p53 gene promoter [83].
Doitsh and colleagues reported that the accumulation of
reverse transcription intermediates in CD4 T cells undergo-
ing abortive HIV-1 infection results in apoptotic death [166].
The apoptotic pathway induced by abortive infection was
associated with the production of inflammatory cytokines,
including IL-1𝛽 and IFN-𝛽, and involved activation of cas-
pase-1 and caspase-3 [166]. However, the authors found no
evidence of p53 involvement [166].
4.4. Viral Restriction Factors. HIV-1 infection and replication
within infected cells can be inhibited at different steps of the
viral life cycle by restriction factors regulated by IFN-I.
4.4.1. Interferon Stimulated Gene 15 (ISG15). The 15 kDa pro-
duct of the IFN-stimulated gene (ISG) 15 was originally
identified as a ubiquitin homologue13. Similar to ubiquitin,
ISG15 acts as a tag for cellular proteins via covalent binding
mediated by specific enzymes, which are also positively regu-
lated by IFN-I [167–170]. However, different from ubiquitin,
the primary effect of tagging with ISG15 (often referred to as
ISGylation) does not appear to be proteasomal degradation.
For example, ISGylation favours the sustained production of
IFN-𝛽 in virus-infected cells by preventing the degradation
of IRF3 [171] and enhances NF-𝜅B signalling by inhibiting the
activity of the protein phosphatase 1B (PPM1B) [172].
ISG15 has been shown to exert broad antiviral activity in
bothmice and humans [167].The anti-HIV-1 activity of ISG15
is mediated via inhibition of the ubiquitylation of the capside
protein Gag and of the cellular protein encoded by the tumor
susceptibility gene (Tsg)101 [173, 174]. Ubiquitylation of Gag
and Tsg101 is required for the release of virions from infected
cells, a processwhich is therefore inhibited by ISGylation [173,
174].
4.4.2. Myxovirus Resistance (Mx) GTPases. Type I IFN ind-
uce the expression of proteins involved in membrane rearr-
angement leading to vesicle budding, organogenesis and
cytokinesis. Some of these proteins may contribute to host
resistance to pathogens, including the p47 and p65 guanylate-
binding proteins (GBP), inducible GTPases and the myx-
ovirus resistance (Mx) proteins [175]. In particular, the Mx
proteins have been widely studied for their antiviral activity
and their expression is strictly regulated by IFN-I [176].
Two Mx proteins have been identified in humans, MxA
and MxB. MxA exerts inhibitory effect on a wide range of
viruses [167]. MxB was recently described as a novel restri-
ction factor for HIV-1 [177, 178]. The mechanism of HIV-
1 inhibition is not fully elucidated, but the viral cycle is
blocked after viral entry and before proviral DNA integration
[177, 178]. In addition, binding to the capsid protein gag is
required for the antiviral activity [177, 178].
4.4.3. 2󸀠-5󸀠-Oligoadenylate Synthetase (OAS) and RNaseL
Pathway. The 2󸀠-5󸀠-oligoadenylate synthetase (OAS) prote-
ins are IFN-I inducible enzymes which polymerize ATP
into oligomers of adenosine generated with noncanonical
2󸀠-5󸀠 bonds [179, 180]. These 2󸀠-5󸀠 adenosine oligomers
induce activation of RNaseL, which mediates degradation
of RNA from invading viruses and suppression of cellular
activities [181]. Degraded RNAmay also activate cytoplasmic
RLR, resulting in IFN-I production and amplification of the
antiviral innate responses [182].
Specific anti-HIV-1 activity by the OAS-RNaseL axis has
been described in transfected cell lines [183]. Although the in
vivo relevance of this antiviral system for HIV-1 inhibition is
still to be determined, it is reasonable to speculate that the
non virus specific effect of RNaseL may partially affect HIV-1
activity in target cells.
4.4.4. Protein Kinase RNA-Activated (PKR). The protein kin-
ase RNA-activated (PKR) is involved, together with other
members of the same family of protein kinases, in the respo-
nse to environmental stress. Kinases in this family regulate
the rate of protein synthesis by phosphorylating the𝛼-subunit
of the eukaryotic initiation factor (EIF) 2, which result in the
sequestration of guanine-nucleotide exchange factor EIF2𝛽,
ultimately preventing the recycle of guanidin diphosphate
(GDP) which is strictly necessary for protein synthesis [184].
PKR is constitutively expressed in all cell types in an
inactive monomeric form and converts active homodimers
following autophosphorylation at key residues [185–188].The
presence of two RNA-binding motifs in the N-terminal
region allows for direct activation of PKR by RNA [189, 190].
PKR is a potent inhibitor of HIV-1 replication in human
cell lines in vitro, but exerts lower inhibitory activity in
primary cells [191–196], questioning the in vivo relevance of
PKR-mediated anti-HIV-1 activity. HIV-1 messenger RNA
contain a target sequence at the 5󸀠 end which is recognized by
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the transactivating accessory protein Tat; the trans-activating
response (TAR)RNAelement plays a critical role in activating
transcription [197–199]. PKR is sensitive to changes in the
cytoplasmic concentration of TAR RNA sequences, in that
low amounts of TAR induce PKR activation, whereas high
TAR RNA concentrations exert an inhibitory effect on PKR
activity [200–202].
4.4.5. Tripartite Motif (TRIM) Proteins. Members of the
tripartite motif (TRIM) protein family participate in a broad
range of cellular functions, including apoptosis and antiviral
immunity [203]. Several TRIM proteins have been described
for their ability to restrict retroviruses replication and many
are directly regulated by IFN-I in humans, including TRIM5
and TRIM22 [204–208].
TRIM5 is one of the best studied members of the
TRIM family, mainly because of its inhibitory activity against
HIV-1. TRIM5 blocks HIV-1 infection in the cytoplasm,
before reverse transcription is completed, by recognizing and
binding the capsid protein lattice, thus interfering with the
uncoating and ultimately with reverse transcription [209].
The antiretroviral effect is strictly dependent on TRIM5 E3
ubiquitin ligase activity [210, 211], and is associated with
proteasome recruitment [212, 213]. TRIM5 itself is ubiqui-
tinated and degraded when it exert inhibitory activity on
restriction-sensitive viruses [210, 211, 214, 215]. However, it is
still unclear whether ubiquitination of HIV-1 capsid occurs.
TRIM5 proteins from different nonhuman primate species
show varying potency of anti-HIV-1 activity. The macaque
and owl monkey TRIM5 orthologues have been particularly
well studied, due to the potent inhibition of HIV-1 infection
in cells from these species [216, 217], which is associated
with strong interaction with the HIV-1 virion core [218]. The
human TRIM5 orthologue shows relatively low inhibitory
activity on lab-adapted HIV-1 stains [205, 219], but it is 10-
fold more potent on certain primary HIV-1 isolates [220].
TRIM5 contributes to control viral transmission and
replication in SIV-infected non human primates [221–225],
and differences in the rate of disease progression in HIV-
1 infected patients correlate with TRIM5 expression and
polymorphisms [226–229]. In addition, Battivelli and col-
leagues reported that HIV-1 variants selected by cytotoxic
T lymphocyte pressure to escape T cell recognition may be
highly sensitive to restriction by human TRIM5 [230].
In addition to its well-studied antiviral activity, TRIM5
has been the subject of studies characterizing its role as a
pattern recognition receptor (PRR) for the protein lattice of
retroviral capsid. TRIM5 is required for dendritic cell acti-
vation in response to lipopolysaccharide (LPS) [211], and
the signal transduction pathways involving AP-1 and NF-𝜅B
are activated by TRIM5 [211, 231]. Thus, the interaction of
TRIM5 with the HIV-1 capsid lattice enhances the induction
of inflammatory cytokines [211].
Other TRIM proteins have been studied for their ability
to interfere with HIV-1 replication. Human TRIM22 effi-
ciently inhibits HIV-1 transcription and replication in pri-
mary human monocyte derived macrophages [232, 233].
TRIM22 exert its antiviral activity after HIV-1 integra-
tion, and E3 ubiquitin ligase activity is not necessary for
TRIM22-mediated inhibition of HIV-1 replication [234].
Depending on the cell type and subcellular localization,
TRIM22 can inhibitHIV-1 transcription at nuclear level [234]
or virion production in the cytoplasm [204].
4.4.6. Apolipoprotein B-Editing Catalytic Polypeptide 3
(APOBEC3) Proteins. The anti-HIV-1 activity of proteins
of the apolipoprotein B-editing catalytic polypeptide 3
(APOBEC3) family was originally described in an effort to
characterize the function of the HIV-1 accessory protein
virion infectivity factor (Vif), which is required for HIV-1
replication in primary CD4+ T cells and certain cell lines, but
not in fully permissive lines. Further studied demonstrated
that the human gene APOBEC3G is a potent inhibitor of the
replication of Vif-deficient HIV-1 [235].
The inhibition ofHIV-1 replication byAPOBEC3G (A3G)
relies on its cytidine deaminase activity on both RNA and
DNA, causing the conversion of cytidine residues into uri-
dines [236–238].This process results in both the alteration of
the nucleotide sequence and the insertion of nonnatural bases
(uredines) into the DNA strand [236–238]. The enzymatic
activity of A3G is selective for the third cytidine in 5󸀠-
CCCA-3󸀠 sequences [237, 238]. As a consequence of cytidine-
to-uridine mutation, the levels of HIV-1 cDNA in infected
cells are diminished. It was initially thought that uredine-
containing DNAwas degraded by host DNA repair enzymes,
but inhibition of uracil DNA glycosidases is ineffective in
restoring HIV-1 cDNA levels [239]. It has been suggested that
A3G activitymay interfere with the progression of the reverse
transcriptase along the viral RNA template [240, 241].
One important characteristic of A3G is the fact that,
unless counteracted by Vif, it is packaged into assembling
HIV-1 virions [242]. Thus, A3G-bearing virions can transfer
the restriction factor to target cells [237, 243–245].
The viral accessory protein Vif potently inhibits the
antiviral activity of A3G by recruiting it for polyubiquiti-
nation and proteasomal degradation, thus preventing A3G
incorporation into newly formed virions [244, 246–248].
Other human APOBEC proteins have been shown to
exert anti-HIV-1 activity in vitro. However, only APOBEC3F
(A3F) and APOBEC3H (A3H) haplotype II appear to have
a significant effect in vivo [249], even though they appear
to have lower potency and lower expression than A3G.
Accordingly, A3G, A3F, andA3H are the only APOBEC3 pro-
teins counteracted by Vif, suggesting a dynamic evolutionary
interplay between host restriction factors and viral escape
mechanisms.
4.4.7. Bone Marrow Stromal Cell Antigen 2 (BST2, Tetherin).
The bone marrow stromal cell antigen 2 (BST2 or tetherin) is
transmembrane protein with glycophosphatidylinositol lipid
anchor at the C-terminal domain, an extracellular 𝛼-helix
domain and a N-terminal transmembrane anchor [250].
Similar to A3G, tetherin was described as the IFN-I-induced
cellular restriction factor inhibited by a HIV-1 accessory
protein, namely Vpu [85, 86, 251, 252]. Thus, in the absence
of Vpu, HIV-1 virions budding from productively infected
cells are trapped or tethered (hence the name tetherin) on
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the surface of infected cells [85, 86, 251, 252]. Tethered virions
are eventually internalization and accumulate in endosomes
[251].
Tetherin exert antiviral activity on several families of
viruses [253–255], and it preserves antiviral activity in the face
of extensive mutations [256], suggesting that its function is
not strictly dependent on recognition of specific viral protein
sequences.
HIV-1 evades the antiviral effect of tetherin thanks to
the accessory protein Vpu [86, 252]. Vpu directly binds teth-
erin, and causes a general decrease in tetherin expression on
the cell surface [252]. Different mechanisms have been sugg-
ested to account for Vpu-mediated counteracting of tetherin
activity, including alterations of trafficking pathways [257,
258], and enhanced proteasomal degradation [259–261].
Other human and nonhuman primate lentiviruses have
developed mechanisms of evasion for tetherin-mediated
antiviral activity. Thus, most SIV do not encode Vpu, and
tetherin is antagonized by the Nef protein [262, 263]. Con-
versely, the Env protein of HIV-2, which also does not encode
Vpu, has evolved to interfere with tetherin and cause it to be
sequestered within intracellular compartments [264, 265].
4.4.8. Sterile 𝛼 Motif (SAM) and Histidine-Aspartic (HD)
Domain-Containing Protein 1 (SMAHD1). Studies on the
function of another lentiviral accessory protein, the viral pro-
tein x (Vpx), brought to the discovery of the restriction factor
sterile 𝛼 motif (SAM) and histidine-aspartic (HD) domain-
containing protein 1 (SMAHD1).
Vpx is expressed by HIV-2 and related viruses (such as
SIVsm) but not by HIV-1 [266]. HIV-1 infection of human
monocyte-derived dendritic cells is enhanced in presence of
exogenous Vpx or if HIV-1 is genetically modified to enco-
de for Vpx [267, 268], and HIV-2 reverse transcription in
monocyte-derived macrophages is strictly dependent on Vpx
[269]. A number of studies contributed to identify SAMHD1
as the target of Vpx-driven ubiquitylation and subsequent
proteosomal degradation. Thus, SAMHD1 ubiquitylation is
mediated by the cullin-4A ubiquitin ligase (CUL4A)-DNA
damage-binding protein 1 (DDB1) complex (CUL4A-DDB1),
which is assembled by Vpx via recruitment of the DDB1
CUL4A associated factor 1 (DCAF1) [270–273].
SAMHD1 exerts phosphohydrolase activity, and can deg-
rade deoxyribonucleotides triphosphate (dNTP) to deoxynu-
cleoside and inorganic triphosphate [274]. Reverse transcrip-
tion relies on the availability of dNTP, and the anti-HIV-
1 effect of SAMHD1 is mediated via its dNTPase activity,
which causes a reduction of the pool of intracellular dNTP
to a level incompatible with viral replication [275]. SAMHD1
is exclusively localized in the nucleus [276–278], whereas
reverse transcription occurs in large part in the cytoplasm,
suggesting that dNTP hydrolysis in the nucleus has deleteri-
ous repercussions on the cytoplasmic availability of dNTP.
SAMHD1 is expressed at constitutively high levels by
cells which are nonpermissive with regards to HIV-1 infec-
tion, such as monocytes and monocyte-derived DC [271].
However, HEK293T cells, undifferentiated THP-1 cells and
activated CD4+ T cells are not refractory to HIV-1 infection
despite expressing SAMHD1 [270, 275], suggesting that the
antiviral activity of SAMHD1 may be biologically important
only in differentiated or non-dividing cells such as DC and
macrophages. The high rate of dNTP turnover in dividing
cells, overcoming the dNTPase activity, may in part explain
the susceptibility to lentiviral infection despite SAMHD1
expression. SAMHD1 can be upregulated in human mono-
cytes and monocyte-derived DC by either type I or type II
IFN [279, 280].
4.5. Immunostimulatory and Modulatory Activites. Type I
IFN play a pivotal role in the transition from innate to ada-
ptive immune responses by both stimulating maturation of
APC and by directly modulating and shaping T cell function.
4.5.1. Effect of IFN-I on APC Differentiation and Maturation.
IFN-I stimulates monocytes differentiation into DC in vitro
[281–284]. However, the presence of IL-4 in the in vitro cul-
ture ofmonocyte appears tomodify the effects of IFN-I, likely
due to the ability of IL-4 to attenuate the expression of ISG
[285]. Thus, the ultimate effect of IFN-I stimulation on the
differentiation of monocytes into DC may depend on the
cytokinemilieu in the surrounding environment and the tim-
ing of exposure to different stimuli.
Importantly, IFN-I promotes the maturation of DC to
fully competent APC by inducing upregulation of the costim-
ulatorymolecules CD40, CD80, and CD86 and by enhancing
the expression of MHC class I and II [6, 7, 286, 287]. These
changes in DC phenotype correspond to increased ability of
IFN-I-stimulated DC to stimulate T cell proliferation in vitro
[6, 7, 286, 287].
Following IFN-I stimulation, DC secrete IL-15, which
exert stimulatory effects on T cells and promotes DCmatura-
tion [282, 288]. In addition, IL-10 and the TNF family mem-
bers B lymphocyte stimulator protein (BlyS) and APRIL are
also expressed by DC following IFN-I stimulation [289–291].
When expressed in combination with IL-10 or transforming
growth factor (TGF)𝛽, APRIL can induce T cell independent
immunoglobulin class switching [291]. IL-10 is a potent anti-
inflammatory mediator, its production in response to IFN-
I highlights the dichotomous role that IFN-I may play in
balancing immune activation and immune suppression [289].
Accordingly, the effect of IFN-𝛼/𝛽 on IL-12 production can be
either stimulatory or inhibitory [292–294]. The maturation
stage of DC and the dose of IFN-I to which they are exposed
may all affect IL-12 production, as well as the interaction of
IFN-I with other stimuli [295, 296]. Changes in the secretion
of IL-12 may then affect the quality of the DC-activated T
cell response bymodulating the induction of IFN-𝛾-secreting
cells as well as the production of other cytokines, such as IL-4,
IL-5, IL-10, and IL-13 [289].
The secretion of chemokine is also modulated by IFN-I.
Monocyte-derived immatureDC secrete the CXCR3-binding
chemokines CXCL9, CXCL11, and CXCL10 in response to
IFN-I stimulation [287]. CXCR3 is expressed by activated T
and B cells [297], which may be recruited to sites of inflam-
mation. In addition, IFN-I induces DC-mediated secretion
of CXCL19 (MIP-3𝛽), which recruits naive T cells and may
therefore contribute to initiating adaptive T cell responses
[298].
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4.5.2.Modulation of T Cell Response. Thedirect effect of IFN-
I on proapoptotic and immunoregulatory ligands, such as
FasL, TRAIL, and PDL1, has been discussed in Section 4.3.
The influence that IFN-I exert on APC maturation and
cytokine production underscore the key role played in the
differentiation of both CD4 and CD8 T cells. Thus, the enha-
ncement of IL-12 production observed whenDC arematured
in presence of IFN-I, induces STAT4 activation and sub-
sequent T-bet expression in CD4 T cells, which drive the
differentiation into IFN-𝛾-producing T helper (Th)1 cells
[299]. In addition, IFN-I directly act on human T cells to
induce STAT4 activation [300, 301], which is however not
sufficient on its own to drive Th1 commitment in vitro [302,
303]. Conversely, in presence of other cytokines, such as IL-18
and IL-21, IFN-I efficiently promotes Th1 cell differentiation
and effector functions [304–306].
In parallel to the positive effects on Th1 differentiation,
IFN-I may inhibit or reverse CD4 T cell differentiation into
other Th types. Thus, Th2 responses are negatively regu-
lated by IFN-I in human cells via the suppression of the
Th2-driving transcription GATA-binding protein 3 (GATA3)
[304]. Furthermore, suppression of Th17 differentiation by
IFN-I has been described in both murine and human cells
[307, 308].
IFN-I may also contribute to negatively modulate T cell
response by regulating the function of CD4 regulatory T
cells (Treg), which play a critical role in the maintenance of
immunological tolerance and homeostasis. Studies conduc-
ted in patients with relapsing-remitting multiple sclerosis
have highlighted how administration of IFN-𝛽 treatment
enhanced both the frequency and suppressive function of
𝑇Reg cells [130].
The primary response of CD8 T cell against viral infec-
tion, epitomized by proliferation and clonal expansion, can
be enhanced in presence of IFN-I, which is also critical in
allowing the generation of memory CD8 T cells [309–311].
However, secondary CD8 and CD4 T cell responses aga-
inst viral antigens, including HIV-1, may be inhibited in
presence of high levels of IFN-I [9, 21]. Thus, the effect of
IFN-I on T cell responses may largely depend on the stim-
ulation condition and the cell types affected, in that IFN-I
may favour costimulatory signals during primary antigen-
specific responses by naive T cells, but suppress secondary
memory responses against recall antigens via the induction
of cytostatic and proapoptotic mechanisms.
5. Conclusion and New Perspectives
Type I IFN play a central role in the coordination of a
multitude of immune effector and regulatory mechanisms.
The ultimate effect of IFN-I on the overall economy of
an effective antiviral immune response may depend on the
mechanism of induction, the cellular source, and the timing
of production.
Plasmacytoid DC may respond rapidly to viral exposure.
The ability of pDC to secrete IFN-I in response TLR7/9
signalling indicates that these cells do not require the viral
genome to enter the cytoplasm, meaning that they produce
IFN-I independent of whether they are productively infected
(Section 2.1). Combining IFN-I productionwith the potential
to mature into APC, pDC may be the ideal candidate to pro-
mote efficient antiviral primary T cell responses, by favouring
CD4 T cell differentiation into Th1 cells and favouring the
activation and clonal expansion of virus-specific naive CD8
T cells (Sections 3.1 and 4.5).The local production of IFN-I
at the site of infection by pDC also favours the induction of
antiviral mechanisms whichmay limit the spread of infection
(Section 4.4).
When productive infection of some tissue target cells is
established, IFN-I production may be sustained by infected
cells which do not normally exert immune function, but can
react to viral genomes in the cytoplasm via specific sensors
(Sections 2.2 and 2.3). Although limited in terms of amount
of IFN-I produced on a per cell basis, this second pDC-
independent wave of IFN-I production may be more focused
and circumscribed to the foci of potential viral replication,
and efficiently inhibit virus spread to other cells without
interfering with adaptive immune responses.
During HIV-1 infection, both the early pDC-mediated
and the late pDC-independent IFN-I responses may be
dysfunctional and cause severe damage to the development
and maintenance of adaptive anti-HIV-1 responses.Thus, the
organization of the HIV-1 envelope into a functional lipid raft
may favour an overwhelming induction of pDC-mediated
persistent IFN-I responses over antigen-presenting function
(Section 3.1), which may prevent the efficient promotion of
primary CD4 Th1 and CD8 T cell responses. Subsequently,
the tropism of HIV-1 for immune cells, including DC
and monocyte/macrophages, may result in the prolonged
production of IFN-I in lymphoid tissues by HIV-1-infected
professional APC, which may compromise the induction of
secondary HIV-1-specific responses and contribute to the
perpetuation of infection and disease progression.
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